Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

A new twist on value has investors waking up to the beauty of companies returning gobs of cash to shareholders.

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B ...

Global markets were subdued as investors braced for further shifts in U.S. trade policy in the wake of President Donald Trump ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...